Amgen earnings matched, revenue topped estimates

Investing.com – Amgen (NASDAQ: AMGN) reported fourth quarter EPS of $4.09, in line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8B versus the consensus estimate of $6.74B.

Guidance

Amgen sees FY 2023 EPS of $17.40-$18.60 versus the analyst consensus of $18.33.

Amgen sees FY 2023 revenue of $26.00B-$27.20B versus the analyst consensus of $27.30B.

Amgen’s stock price closed at $252.40. It is down -5.07% in the last 3 months and up 10.37% in the last 12 months.

Amgen saw 8 positive EPS revisions and 8 negative EPS revisions in the last 90 days. See Amgen’s stock price’s past reactions to earnings here.

According to InvestingPro, Amgen’s Financial Health score is “good performance”.

Check out Amgen’s , and Amgen’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar